N
Nohla Therapeutics
Developing an shelf alternative to bone marrow transplants
About Nohla Therapeutics
Nohla Therapeutics, founded in 2015 by Dr. Colleen Delaney, operated as a clinical-stage cellular therapy company focused on developing off-the-shelf treatments for patients with critical hematological diseases. The company was established as a spin-out from the Fred Hutchinson Cancer Research Center to commercialize a technology platform developed over two decades. Dr. Delaney, a physician-scientist with a background from Harvard Medical School and extensive research at Fred Hutch, pioneered the methods for making umbilical cord blood transplants more successful and widely available. Her work led to the creation of a proprietary platform that expands the number of stem and progenitor cells from umbilical cord blood donations by up to 500 times.
The company's core business revolved around this ex vivo umbilical cord blood expansion platform, which creates universal donor cellular therapies. These therapies were designed to be used on-demand without the need for Human Leukocyte Antigen (HLA) matching, providing a significant advantage over traditional bone marrow transplants that require a close biological match. The business model focused on advancing its lead product candidates through clinical trials to gain regulatory approval and then commercialize them. Its primary clients were patients with life-threatening hematological malignancies, such as acute myeloid leukemia (AML), who were undergoing intensive chemotherapy. The company's lead product, known as dilanubicel (NLA101), was an expanded hematopoietic stem and progenitor cell therapy. It was developed to provide a temporary bridge of infection-fighting cells, promoting rapid hematopoietic recovery and reducing the risk of infection while the patient's own immune system recovered post-treatment.
Throughout its operation, Nohla Therapeutics achieved several milestones. The company launched in late 2015, securing a 20-year exclusive licensing agreement with the Fred Hutchinson Cancer Research Center and raising significant initial funding. It successfully raised a total of $120 million over four funding rounds, with its Series A in 2016 bringing in $43.5 million and a Series B round in 2018 totaling $56 million from investors including ARCH Venture Partners, Fidelity, and Celgene. The company advanced its lead product, dilanubicel, into multiple Phase 2 clinical trials for applications in allogeneic transplant and AML. In early 2017, Kathleen Fanning, a biotech executive with over 30 years of experience, was appointed President and CEO to guide the company through clinical development and manufacturing ramp-up. Despite its progress, the company ceased operations in late 2019. Following her time at Nohla, Dr. Delaney founded Deverra Therapeutics in 2020 to continue her work in cellular immunotherapies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2018 | $11M | $44M | Premier Partners · Schroder Adveq · UTEC - The University of Tokyo Edge Capital Partners | — |
| SERIES BOther financing | May 2018 | $45M | $180M | 5AM Ventures · ARCH Venture Partners · Celgene · AML Partners | — |
Growth signals
Latest recorded traffic for Nohla Therapeutics is 50 monthly website visits. Nohla Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nohla Therapeutics in the Seattle ecosystem
The Nohla Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
ARCH Venture Partners
5AM Ventures
Fidelity Investments
Bristol-Myers Squibb
Celgene
AML Partners
Alexandria Venture Investments
Schroder Adveq
UTEC - The University of Tokyo Edge Capital Partners
Premier Partners
Other known investors1 additional known investor
Fred Hutchinson Cancer Research Center
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nohla Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nohla Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










